The Efficacy of Intralesional Platelet-rich Fibrin Injection Compared to Intralesional Normal Saline Injection of Melasma: A Randomized, Split-face, Prospective Control Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20260310005

Enrollment

Registered

2026-03-10

Start date

2026-04-20

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma Melasma, chloasma, chloasma faciei, platelet rich fibrin, PRF, Autologous platelet concentration, APC

Interventions

Intralesional platelet-rich fibrin was injected into the melasma lesions on one side of the face as the experimental side.,Intralesional normal saline was injected into the melasma lesions on another

Experimental Biological/Vaccine,Placebo Comparator Biological/Vaccine

Platelet-rich fibrin injection,Normal saline injection

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Thai, age 18-65 yr., no sex specific 2. Melasma on both side of the face 3. Limit daily light exposure 4. Apply SPF 50 sunscreen on the face daily 5. Able to attened all schedule visits and complete the study

Exclusion criteria

Exclusion criteria: 1. Currently undergoing treatment for melasma or other pigmentary disorders within the past 6 months. 2. Use of depigmenting agents or agents that inhibit melanin production, either topical or oral. 3. History of any cosmetic or medical procedures that may affect skin color changes in the study area. 4. Having underlying diseases, or taking medications or dietary supplements that affect blood coagulation. 5. Receiving hormonal therapy. 6. Having health conditions that may affect skin pigmentation changes, including autoimmune diseases, diabetes mellitus, cancer, or inflammatory/infectious skin diseases at the treatment site. 7. History of chronic alcohol consumption or smoking. 8. Currently pregnant or breastfeeding. 9. History of allergy to local anesthetics or antiseptics containing chlorhexidine in alcohol.

Design outcomes

Primary

Measure	Time frame
Modified Melasma Area and Severity Index At 10 weeks after last visit Two dermatologists independently evaluated the modified Melasma Area and Severity Index (mMASI) scores using standardized clinical photographs.	—

Secondary

Measure	Time frame
Melanin index At 10 weeks after last visit Mexameter,Global Aesthetic Improvement Scale At 10 weeks after last visit Quesionnaires	—

Countries

Thailand

Contacts

Public ContactGynna Techataweewan

Dhurakij Pundit University

67130426@dpi.ac.th033056195

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026